Introduction
Attention deficit / hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder, with an estimated prevalence of around 5%. While a proportion of cases remits, a significant part of the patients do not fully recover and feature full or partial persistence of the disorder into adulthood, then termed adult ADHD (aADHD) (Faraone and others 2006) . The childhood manifestation of the disorder is highly heritablearound 80% (Faraone and Khan 2006; Franke and others 2012 ) -and so is aADHD, when clinical diagnostic instruments are used (Larsson and others 2013) . However, despite considerable efforts e.g. in consortia such as the Psychiatric Genomics Consortium, only few risk genes have been yet discovered and confirmed. This likely is due to the complex genetic architecture of ADHD involving common as well as rare variants, be it in the form of base pair mutations or copy number variants. This is even more true for the adult form of ADHD, where there are considerably less studies on risk genes (Franke and others 2012) . Looking across the lifespan, it can be hypothesized that, in addition to genes predisposing to ADHD onset as such, genetic variance impacts on the persistence of the disorder (Chang and others 2013) -in fact, there is already one example where one allele of a polymorphism is associated with childhood ADHD, while the other allele is associated with adult ADHD (the gene encoding the dopamine transporter DAT (Franke and others 2010) ). Finally, it is known that aADHD goes along with a high rate of both psychiatric (Jacob and others 2014a; Jacob and others 2014b; Jacob and others 2007) as well as somatic (Haavik and others 2010) comorbidities. Many of those comorbid phenomena have a heritable basis as well (e.g., (Lee and others 2013) ), but only few risk variants for such comorbidity have been identified (e.g., (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013)).
We have previously identified a highly polymorphic repeat in the promoter region of the gene encoding nitric oxide synthase 1 (NOS1), termed NOS1 ex1f-VNTR, short alleles of which results in lower gene expression in vitro; supposedly such reduced expression is also present in the basal ganglia, as the specific splice form is predominantly expressed in this part of the brain (Freudenberg 2015; Reif and others 2006; Reif and others 2009; Rife and others 2009 ). The gene product, NOS-I, is the sole source for the gaseous neurotransmitter NO in the brain, which is also the second messenger of the NMDA receptor, and which is involved in learning, memory, behavioral control and emotional behaviors (Snyder and F o r P e e r R e v i e w others 1998). Mice that lack fully functional Nos-I are more aggressive, impulsive, less anxious and cognitively impaired (Nelson and others 2006; Wultsch and others 2007) . These data make NOS1 an excellent candidate gene for ADHD and associated impulsive behaviors.
Although we could not establish a role for NOS1 ex1f-VNTR in childhood ADHD (potentially because of sample size limitations), we have earlier demonstrated that short (i.e, lowexpression) variants of the NOS1 repeat polymorphism are associated with aADHD as well as a wide range of impulsive behaviors including aggression, suicidality, and cluster B personality disorder (Reif and others 2009 ). The association with impulsive personality domains was sex-specific and found in females only: re-analysis of the case-control data reported in Reif and others (2009) revealed no significant association in males, but association of short alleles with aADHD in the females (OR=1.26, p=0.04; genotypic p-value assuming a recessive effect = 0.009).
We later replicated the association with impulsive traits in Estonian samples (Laas and others 2010) , and also observed a gene × environment interaction (Reif and others 2011a) . Also, emotional behaviors were found to be influenced by this polymorphism (Kurrikoff and others 2012) . Further substantiating an association of NOS1 with behavioral traits, brain activation during working memory (Kopf and others 2011) and impulsivity (Kopf and others 2012) tasks was shown to be altered by the presence of the short NOS1 alleles.
Unfortunately, the ex1f-VNTR is not tagged by single nucleotide polymorphisms (SNPs) in genome-wide association studies (GWAS), and no hypothesis-free approaches have yet confirmed the association with ADHD (although a SNP was found suggestively associated with quantitative ADHD symptoms in an early ADHD GWAS (Franke and others 2009) 
Material and Methods

Genotyped samples
The discovery case-control sample, previously published in part (Reif and others Inclusion criteria were onset before the age of 7 years, life-long persistence, current diagnosis and age of recruitment between 18 and 65 years. Childhood ADHD was retrospectively assessed with the DSM-IV symptom list for ADHD (17 items) that was used as a structured clinical interview, and additionally using the Wender-Utah Rating Scale (WURS; 61 items). Personality assessment was done using NEO PI-R (Costa 1992 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w affect the allele frequency of an associated polymorphism. Allele frequencies of the NOS1 ex1f-VNTR however did not differ between screened and unscreened controls (p>>0.05).
Two further aADHD samples were obtained from IMpACT (Franke and others 2010; Halmoy and others 2010; Johansson and others 2008; Reif and others 2011b) . The total replication sample included 710 aADHD patients (mean age 30.6 years, SD 11.5; 39% female) and 847 controls (mean age 48.7 years, SD 14.5; 45% female) of Norwegian (n cases =416; n controls =535) and Spanish (n cases =294; n controls =312) origin. All patients were evaluated by experienced psychiatrists and diagnosed with persistent ADHD according to DSM-IV criteria using standardized clinical interviews. Consensus eligibility criteria for this study across all study sites were a diagnosis of ADHD according to the diagnostic criteria of DSM-IV, age at onset <7 years by retrospective diagnosis (which was confirmed by family members, wherever possible), life-long persistence, and current diagnosis. Norwegian controls were free of psychotropic medication, but not screened for psychiatric disorders; Spanish healthy volunteers were screened for and free of psychiatric disorders. Further information on replication samples can be obtained from Supplementary Table I. All patients and volunteers provided written informed consent after oral and written explanation about scope and aim of the investigation. The studies complied with the Declaration of Helsinki and were approved by the local ethical committees of the respective universities.
Genotyping of NOS1 ex1f-VNTR
The highly polymorphic ex1f-VNTR repeat, located in the upstream region of NOS1 (GRCh 38: 117361839bp-117361898bp), consists mainly of 19 to 36 and in rare cases of 8 or 15 "GT" dinucleotide units. To facilitate genetic association studies, NOS1 ex1f-VNTR alleles were dichotomized in short (8, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) repeats, "S") and long (28-36 (GT) repeats, "L") alleles based on the historical median split; prevalent "S" and "L" alleles differ in promoter activation (Reif and others 2009) and the split was defined between rare alleles (Figure 1 ).
Genomic DNA for genotyping was extracted from venous blood of all participants, by a standard de-salting method. NOS1 ex1f-VNTR alleles were identified using a polymerase chain reaction (PCR) amplification step followed by electrophoretic separation and product size determination on a DNA sequencer (CEQ8000; Beckman-Coulter, Krefeld, Germany) as 
Meta-analysis
To obtain maximal information regarding the NOS1 ex1f-VNTR, we conducted a meta-analysis of the German, Norwegian and Spanish samples and thereby achieve a pooled sample power of 70% assuming a co-dominant model, a MAF of 0.05 (Power for Genetic Association version 2.0) and a relative risk of 1.25 to develop aADHD.
Meta-analyses were performed with the R package metaphor version 0.5-7 (Viechtbauer 2009) using the "rma" command. As a measure for effect size, we calculated odds ratios (ORs) and applied the Q-statistic (Fleiss 1981; Lau and others 1997) to assess heterogeneity therein. Inconsistency across studies was quantified with the I^2 metric (I^2=(Q-df)/Q). The joint OR was determined as the weighted average of effect sizes entering the meta-analysis. When the Q-statistic showed no heterogeneity in the effect sizes, we applied fixed-effects models (Mantel and Haenszel 1959) , where the weights correspond to the inversed variances of the study ORs. In the presence of significant (p<0.05)
heterogeneity, we applied random-effects models (DerSimonian and Laird 1986). Here, weights are initially calculated as in the fixed-effects model, but are then down-weighted by the degree of variance of effect sizes.
Influence of NOS1 ex1f-VNTR on mRNA expression
The influence of NOS1 ex1f-VNTR on mRNA expression was examined in 
Results
Association analysis of NOS1 ex1f-VNTR in three independent aADHD case-control samples
Due to different geographic origin of our study samples, allelic and recessive model associations were first determined separately in each sample; a meta-analysis was then conducted to assess the statistical significance of the pooled effect sizes with maximal statistical power (Table I and Figure 2, Supplementary Figure 1) . When all three samples were analyzed jointly using a meta-analytic approach with a sample size totaling to 1,697 cases and 2,866 controls, short alleles were significantly associated with aADHD, however only when the analysis was restricted to females (P Fixed =0.049; OR=1.14 [95% CI: 1.00-1.29]; Figure 2B ) as it was the case in the discovery sample.
To test which of the 19 NOS1 ex1f-VNTR alleles conveys the genetic predisposition towards aADHD, additional allelic case-control analyses were conducted for each of the 19 repeats, versus all other repeats (Supplementary Table III Supplementary Table IV) .
Association analysis of NOS1 ex1f-VNTR with aADHD clinical presentations
To examine whether NOS1 ex1f-VNTR is specifically linked to one of the ADHD subphenotypes (inattentive (AD), hyperactive/impulsive (HD), or combined (AD+HD) presentation), we performed allelic and recessive model association analyses with all three ADHD clinical presentations by meta-analysis (Table II, Supplementary Table V Supplementary Table VI) .
Association analysis of NOS1 ex1f-VNTR with comorbid disorders
In an exploratory manner, we assessed the impact of NOS1 ex1f-VNTR on comorbid disorders, specifically Substance Abuse (Alcohol: SUDAlc and Drugs: SUDDrug), Major Depression (MD), Anxiety Disorder (AnxDis), Personality Disorders Cluster A (CL_A), B (CL_B) and C (CL_C), and Migraine (Migr), in the German, Norwegian and Spanish samples (see Tables III and IV and Supplementary Tables VII and VIII Figure 6) . Unfortunately, no other brain regions were available for further analysis.
Discussion
The present study aimed to corroborate the association of NOS1 ex1f-VNTR with aADHD (Reif and others 2009) and related phenotypes (Freudenberg 2015) . The association with aADHD in the original study was specific to females, but no attempt at replication has been published to date. We almost tripled the size of the original discovery sample (Reif and others 2009) and furthermore added two independent samples for meta-analysis. Overall, our data confirmed a sex-specific association of NOS1 ex1f-VNTR with aADHD, especially with clinical presentations featuring hyperactive/impulsive symptoms and also with comorbid AnxDis, MD, CL_C and Migr.
In reporter gene assays, short repeat lengths consistently resulted in lower gene expression as shown by two independent groups (Reif and others 2009; Rife and others 2009 ). In contrast, we here detected increased NOS1 expression in the amygdala in short allele carriers. However, despite it is well known that NOS1 is expressed in the amygdala, it is unclear which alternative first exon (and hence alternative promoter) drives expression in this structure. As the effect of the NOS1 ex1f-VNTR genotype may be highly tissue-specific, and also as we measured total NOS1 driven from alternative promoters, our data might represent compensatory up-regulation of total NOS1 in response to decreased NOS1 ex1f expression either in the amygdala as such or elsewhere. Also, since both cell lines used for were originally derived from cancer tissue of female donors, whereas the post-mortem brain sample was mainly composed of male specimens (76%), one may speculate that the observed discordance of S allele effects reflects the sex differences found in the association studies (see below). Further studies in larger samples of human tissue are clearly warranted to clarify the molecular effect of the NOS1 ex1f-VNTR.
Association of NOS1 with adult ADHD
Our initial finding (Reif and others 2009) , namely that short NOS1 ex1f-VNTR alleles are associated with aADHD in females, was successfully replicated in the German sample. A validation using Spanish and Norwegian samples did however not succeed; differences in the genetic background due to the ethnic composition of the samples as well as sample size constraints (sample sizes were not even half as large as the German sample) provide plausible explanations for the failure to replicate. Meta-analysis of NOS1 ex1f-VNTR of three samples however confirmed the sex-specific association; since sex distribution in samples was almost balanced, power considerations may rather not explain the observed differences between males and females. Hence, biological mechanisms might form an alternative explanation, and in this context it is noteworthy that a cis-acting estrogen binding site is present directly upstream of the NOS1 ex1f-VNTR, so that effects of sex hormones on NOS1 expression seem plausible. Sex-specific associations with NOS1 ex1f-VNTR were previously observed in an independent sample representing the general population (Kurrikoff and others 2012) . Moreover, in murine models for aggression, effects of Nos1 deficiency were shown in both sexes, however in the opposing direction: male mice became more (Chiavegatto and others 2001) and female mice became less aggressive (Gammie and Nelson 1999 ). The latter observation was confirmed by a selective breeding approach, where mice selected for high maternal aggression were found to have increased Nos1 expression (Gammie and others 2007) . Sex effects thus should be explicitly addressed in further studies on NOS1's role in behavior and psychopathology.
Despite considerable sample size, our data is not definitive as the strength of association is not very pronounced; also, the effect in the German sample was the most significant, suggesting that the association of NOS1 with aADHD follows the "winner's curse". However, the finding that short alleles convey risk across all published studies (Freudenberg 2015) and also in the present dataset supports the hypothesis that psychiatric (Freudenberg 2015) . Also, the rather crude distinction in short and long alleles (originally merely based on statistical reasons, i.e. the median repeat length) might obscure biological effects. A more detailed analysis of all individual alleles suggested the 21-repeats to be associated with the phenotypes in question, at least in the German sample.
Although here, respective calculations yielded stronger significance levels and thus greater effect sizes as compared to the short/long dichotomized polymorphism, discordant results were obtained from the Norwegian and Spanish samples, thus demanding further and larger samples to detail if the genetic risk is indeed conveyed by the 21-repeat allele.
aADHD subtype and comorbid disorders
As the IMpACT samples are well characterized and broadly phenotyped, this provided the opportunity to run exploratory analyses on dimensional traits and co-morbid conditions anxiety. In the context of aADHD, as tested in the present study, both affective and anxiety disorders seem to be linked to short alleles of NOS1 ex1f-VNTR indicating that NOS1 may also have a role in emotional behaviors in humans. Regarding substance use disorders, a role for NOS1 could especially be assumed given data from knockout mice (Spanagel and others 2002) ; however, no effect could be found in our human sample. This of course does not rule out a role for NOS-I in alcohol abuse, but argue against a major contribution through a common genetic variant in the gene. Also, we could not replicate our previous finding (Reif Previously we have presented evidence for comorbidity between ADHD and migraine (Fasmer and others 2011) . The association between NOS1 and migraine in ADHD patients is interesting (Table III) Taken together, the present study strengthens the notion that short allelespotentially the 21-repeat allele -of NOS1 ex1f-VNTR are associated with aADHD in a sex specific manner; its role likely is complex with effects on hyperactivity/impulsivity, stressrelated disorders, migraine and IQ. NOS-I thus might be a molecular link between these phenotypes, explaining at least a little genetic part of the observed co-morbidity of ADHD with these phenotypes. This hypothesis could be directly tested in further studies, and also, functional studies are warranted to elucidate the neurobiological pathways that link genetic variation to neural systems and behavior. 
Tables (4)
Table I: Association results for the NOS1 ex1f-VNTR in the German, Norwegian and Spanish samples, followed by meta-analysis. Table shows allele and genotype counts for cases and controls, as well as χ2-and the p-value of the calculated allelic (S-alleles vs. L-alleles) and recessive (SS vs. SL+LL) and models in the total sample, and their sex-specific subsets. Further, total cases and control counts are given for the allelic and recessive models as well as p-values for heterogeneity and odds ratios plus p-values of the fixed effect model. Bold face indicates significant p-values (p<0.05). Table II : Association results of aADHD clinical presentations (inattentive (AD), hyperactive (HD), and combined (AD+HD) type ADHD) for the NOS1 ex1f-VNTR in the German, Norwegian and Spanish sample, followed by a meta-analysis. Along allele counts for cases and controls, the χ2-and the pvalue of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender specific subsets are shown. Further, total cases and control counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model are given. Bold face indicates significant p-values (p<0.05). Table III : Association results of NOS1 ex1f-VNTR with comorbid axis 1 disorders (Substance Abuse (Alcohol: SUDAlc and Illicit Drugs: SUDDrug), Major Depression (MD), Anxiety Disorder (AnxDis)) in the German, Norwegian and Spanish samples, followed by meta-analysis. Along allele and genotype counts for cases and controls, the χ2-and the p-value of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender specific subsets are shown. Further, total cases and control allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model are given. Bold face indicates significant p-values (p<0.05). Table IV : Association results of NOS1 ex1f-VNTR with comorbid co-morbid axis 2 and somatic disorders (Personality Disorder Cluster A (CL_A), B (CL_B) and C (CL_C), Migraine (Migr)) in the German, Norwegian and Spanish sample, followed meta-analysis. Along allele and genotype counts for cases and controls, the χ2-and the p-value of the calculated allelic (S-alleles vs. L-alleles) model in the total sample, as well as their gender specific subsets are shown. Further, total cases and control allele counts, p-values for heterogeneity and odds ratios plus p-values of the fixed effect model are given. Bold face indicates significant p-values (p<0.05). (Reif and others, 2009 ) and recent aADHD samples using allelic (S-alleles vs. L-alleles) and recessive (SS vs. SL+LL) models. Bold face indicates significant p-values (p<0.05).
Supplementary Figures (6)
Supplementary
Supplementary Table III: Distribution of the 19 NOS1 ex1f-VNTR-repeat alleles
Supplementary Table IV:
Association results for the 21-repeat allele of NOS1 ex1f-VNTR in the German, Norwegian and Spanish samples, followed by meta-analysis. Along allele counts for cases and controls, the χ2-and the p-value of the calculated allelic (21-repeat-alleles vs. all other alleles) model in the total sample, as well as their gender specific subsets are shown. Further, total cases and control counts, p-values for heterogeneity and odds ratios plus p-values of the fixed or random effect model are given. Bold face indicates significant p-values (p<0.05). 
Supplementary Table IX:
Association results of the 21-repeat allele of NOS1 ex1f-VNTR with comorbid disorders (major depression (MD), anxiety disorders (AnxDis), migraine (Migr) for in the German, Norwegian and Spanish sample, followed by meta-analysis. Along allele counts for cases and controls, the χ2-and the p-value of the calculated allelic (21-repeat alleles vs. all other alleles) model in the total sample, as well as their gender specific subsets are shown. Further, total cases and control counts, p-values for heterogeneity and odds ratios plus p-values of the fixed or random effect model are given. Bold face indicates significant p-values (p<0.05).
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